vs

Side-by-side financial comparison of Monte Rosa Therapeutics, Inc. (GLUE) and LCNB CORP (LCNB). Click either name above to swap in a different company.

LCNB CORP is the larger business by last-quarter revenue ($23.9M vs $12.8M, roughly 1.9× Monte Rosa Therapeutics, Inc.). LCNB CORP runs the higher net margin — 23.7% vs -212.1%, a 235.8% gap on every dollar of revenue. On growth, Monte Rosa Therapeutics, Inc. posted the faster year-over-year revenue change (38.5% vs 5.1%). Monte Rosa Therapeutics, Inc. produced more free cash flow last quarter ($99.8M vs $33.4M).

Monte Rosa Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of targeted molecular glue degrader therapies. Its pipeline addresses unmet medical needs across oncology, rare genetic disorders and immunological diseases, with operations focused on advancing novel treatments for global patient populations.

LCNB Corp is a United States-based financial holding company that operates through its national bank subsidiary, providing a full suite of retail and commercial banking products and services including deposit accounts, various loan products, wealth management, and insurance solutions primarily to individual consumers, small and medium-sized enterprises and local community organizations across regional markets in Ohio.

GLUE vs LCNB — Head-to-Head

Bigger by revenue
LCNB
LCNB
1.9× larger
LCNB
$23.9M
$12.8M
GLUE
Growing faster (revenue YoY)
GLUE
GLUE
+33.4% gap
GLUE
38.5%
5.1%
LCNB
Higher net margin
LCNB
LCNB
235.8% more per $
LCNB
23.7%
-212.1%
GLUE
More free cash flow
GLUE
GLUE
$66.3M more FCF
GLUE
$99.8M
$33.4M
LCNB

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
GLUE
GLUE
LCNB
LCNB
Revenue
$12.8M
$23.9M
Net Profit
$-27.1M
$5.7M
Gross Margin
Operating Margin
-258.3%
29.2%
Net Margin
-212.1%
23.7%
Revenue YoY
38.5%
5.1%
Net Profit YoY
-13.5%
-7.6%
EPS (diluted)
$0.40

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GLUE
GLUE
LCNB
LCNB
Q4 25
$23.9M
Q3 25
$12.8M
$23.8M
Q2 25
$23.2M
$22.8M
Q1 25
$84.9M
$21.5M
Q4 24
$60.6M
$22.7M
Q3 24
$21.4M
Q2 24
$19.3M
Q1 24
$17.8M
Net Profit
GLUE
GLUE
LCNB
LCNB
Q4 25
$5.7M
Q3 25
$-27.1M
$6.9M
Q2 25
$-12.3M
$5.9M
Q1 25
$46.9M
$4.6M
Q4 24
$13.4M
$6.1M
Q3 24
$4.5M
Q2 24
$925.0K
Q1 24
$1.9M
Operating Margin
GLUE
GLUE
LCNB
LCNB
Q4 25
29.2%
Q3 25
-258.3%
35.6%
Q2 25
-67.1%
31.6%
Q1 25
51.9%
25.6%
Q4 24
21.4%
32.9%
Q3 24
24.9%
Q2 24
4.9%
Q1 24
12.5%
Net Margin
GLUE
GLUE
LCNB
LCNB
Q4 25
23.7%
Q3 25
-212.1%
29.1%
Q2 25
-53.0%
26.0%
Q1 25
55.2%
21.4%
Q4 24
22.2%
27.0%
Q3 24
21.2%
Q2 24
4.8%
Q1 24
10.7%
EPS (diluted)
GLUE
GLUE
LCNB
LCNB
Q4 25
$0.40
Q3 25
$0.49
Q2 25
$0.41
Q1 25
$0.33
Q4 24
$0.44
Q3 24
$0.31
Q2 24
$0.07
Q1 24
$0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GLUE
GLUE
LCNB
LCNB
Cash + ST InvestmentsLiquidity on hand
$208.3M
$21.6M
Total DebtLower is stronger
$104.4M
Stockholders' EquityBook value
$245.8M
$273.9M
Total Assets
$459.8M
$2.2B
Debt / EquityLower = less leverage
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GLUE
GLUE
LCNB
LCNB
Q4 25
$21.6M
Q3 25
$208.3M
$35.9M
Q2 25
$69.4M
$49.8M
Q1 25
$78.5M
$37.7M
Q4 24
$224.3M
$35.7M
Q3 24
$39.4M
Q2 24
$34.9M
Q1 24
$33.0M
Total Debt
GLUE
GLUE
LCNB
LCNB
Q4 25
$104.4M
Q3 25
$104.7M
Q2 25
$105.0M
Q1 25
$104.6M
Q4 24
$155.2M
Q3 24
$155.7M
Q2 24
$162.2M
Q1 24
$162.6M
Stockholders' Equity
GLUE
GLUE
LCNB
LCNB
Q4 25
$273.9M
Q3 25
$245.8M
$269.9M
Q2 25
$268.1M
$263.5M
Q1 25
$275.2M
$258.7M
Q4 24
$222.9M
$253.0M
Q3 24
$253.2M
Q2 24
$245.2M
Q1 24
$233.7M
Total Assets
GLUE
GLUE
LCNB
LCNB
Q4 25
$2.2B
Q3 25
$459.8M
$2.2B
Q2 25
$359.6M
$2.3B
Q1 25
$393.2M
$2.3B
Q4 24
$438.7M
$2.3B
Q3 24
$2.3B
Q2 24
$2.4B
Q1 24
$2.3B
Debt / Equity
GLUE
GLUE
LCNB
LCNB
Q4 25
0.38×
Q3 25
0.39×
Q2 25
0.40×
Q1 25
0.40×
Q4 24
0.61×
Q3 24
0.61×
Q2 24
0.66×
Q1 24
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GLUE
GLUE
LCNB
LCNB
Operating Cash FlowLast quarter
$100.4M
$34.4M
Free Cash FlowOCF − Capex
$99.8M
$33.4M
FCF MarginFCF / Revenue
781.5%
140.2%
Capex IntensityCapex / Revenue
5.1%
4.0%
Cash ConversionOCF / Net Profit
6.08×
TTM Free Cash FlowTrailing 4 quarters
$145.0M
$54.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GLUE
GLUE
LCNB
LCNB
Q4 25
$34.4M
Q3 25
$100.4M
$14.0M
Q2 25
$-34.7M
$5.5M
Q1 25
$-45.5M
$2.2M
Q4 24
$128.9M
$93.2M
Q3 24
$11.9M
Q2 24
$54.9M
Q1 24
$-11.9M
Free Cash Flow
GLUE
GLUE
LCNB
LCNB
Q4 25
$33.4M
Q3 25
$99.8M
$13.7M
Q2 25
$-36.4M
$5.2M
Q1 25
$-47.1M
$2.1M
Q4 24
$128.7M
$89.4M
Q3 24
$10.5M
Q2 24
$53.8M
Q1 24
$-12.8M
FCF Margin
GLUE
GLUE
LCNB
LCNB
Q4 25
140.2%
Q3 25
781.5%
57.4%
Q2 25
-157.0%
23.0%
Q1 25
-55.4%
10.0%
Q4 24
212.3%
394.0%
Q3 24
49.0%
Q2 24
278.6%
Q1 24
-71.8%
Capex Intensity
GLUE
GLUE
LCNB
LCNB
Q4 25
4.0%
Q3 25
5.1%
1.3%
Q2 25
7.3%
1.0%
Q1 25
1.9%
0.3%
Q4 24
0.3%
16.7%
Q3 24
6.7%
Q2 24
5.9%
Q1 24
4.8%
Cash Conversion
GLUE
GLUE
LCNB
LCNB
Q4 25
6.08×
Q3 25
2.02×
Q2 25
0.92×
Q1 25
-0.97×
0.48×
Q4 24
9.59×
15.23×
Q3 24
2.63×
Q2 24
59.35×
Q1 24
-6.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons